Cheryl Ho

A. Tremblay, D. Palma, M. Liberman, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary Tumor Resection in Patients Presenting With Metastatic Colorectal Cancer: Analysis of a Provincial Population-Based Cohort

S. Gill, Cheryl Ho, T. Chan, 2010, American journal of clinical oncology.

Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

L. Stitt, D. Rayson, D. Jonker, 2016, Clinical colorectal cancer.

Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.

L. Stitt, E. Winquist, M. Vincent, 2002, Clinical colorectal cancer.

Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.

S. Gill, Cheryl Ho, S. O'Reilly, 2005, Clinical colorectal cancer.

Radical Treatment of Stage II Non–small‐cell Lung Cancer With Nonsurgical Approaches: A Multi‐institution Report of Outcomes

J. Pantarotto, N. Leighl, P. Wheatley‐Price, 2018, Clinical lung cancer.

Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.

A. Davies, Cheryl Ho, H. Ross, 2006, Clinical lung cancer.

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.

B. Melosky, H. Anderson, Cheryl Ho, 2005, Lung cancer.

Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer

L. Beckett, D. Gandara, A. Davies, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cheryl Ho, N. Murray, F. Anderson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study

L. Beckett, D. Gandara, A. Davies, 2007, Investigational New Drugs.

Magnetic Resonance Imaging Volumetry of Primary Nasopharyngeal Cancer in Patients Treated with Induction Gemcitabine and Cisplatin Followed by Concurrent Cisplatin and Volumetric Modulated Arc Therapy

Jonn Wu, E. Berthelet, E. Tran, 2018, Cureus.

Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.

D. Ionescu, Cheryl Ho, Gang-ping Wang, 2021, Cancer treatment and research communications.

Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.

Gang Wang, D. Ionescu, Cheryl Ho, 2020, Annals of diagnostic pathology.

Patterns of Radiotherapy Utilization for Lung Cancer Patients with Brain Metastases: A Population-based Analysis

I. Fraser, R. Olson, Cheryl Ho, 2019, Cureus.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

L. Seymour, K. Ding, F. Shepherd, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anticipating the Next Step in the Management of ALK-Positive NSCLC.

Cheryl Ho, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Implementation of a Lung Cancer Nurse Navigator Enhances Patient Care and Delivery of Systemic Therapy at the British Columbia Cancer Agency, Vancouver.

Cheryl Ho, J. Laskin, K. Zibrik, 2016, Journal of oncology practice.

A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy

W. Cheung, Cheryl Ho, J. Laskin, 2017, Thyroid Research.

Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab

S. Yip, E. Chan, Cheryl Ho, 2022, Cureus.

Asian Versus Non-Asian Outcomes in Nasopharyngeal Carcinoma: A North American Population-based Analysis

Jonn Wu, S. Hamilton, Cheryl Ho, 2016, American journal of clinical oncology.

Impact of Neoadjuvant Chemotherapy on the Administration of Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma

E. Berthelet, S. Hamilton, Cheryl Ho, 2018, Cureus.

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

L. Seymour, M. Tsao, F. Shepherd, 2017, Oncotarget.

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

L. Beckett, J. Riess, D. Gandara, 2013, Investigational New Drugs.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer

Steven J. M. Jones, A. Gown, E. Pleasance, 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141

K. Harrington, M. Monga, E. Vokes, 2017 .

Dose Delivery Analysis of Weekly Versus 3-Weekly Cisplatin Concurrent With Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Jonn Wu, D. Hao, Cheryl Ho, 2014, American journal of clinical oncology.

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

Trevor J Pugh, D. Horsman, M. Marra, 2007, BMC Cancer.

EGFR-directed therapies to treat non-small-cell lung cancer

Janessa Laskin, Cheryl Ho, Cheryl Ho, 2009, Expert opinion on investigational drugs.

The neoantigen landscape of the coding and noncoding cancer genome space.

E. Pleasance, A. Karsan, E. Titmuss, 2022, The Journal of molecular diagnostics : JMD.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non–Small-Cell Lung Cancer Clinical Trials

Cheryl Ho, N. Murray, J. Laskin, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.

Sophie Sun, B. Melosky, Cheryl Ho, 2014, Lung cancer.

Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.

Cheryl Ho, J. Laskin, K. M. Tong, 2015, Lung cancer.

Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer

Cheryl Ho, B. Weber, R. Yuan, 2016, Journal of Neuro-Oncology.

Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study

S. Yip, B. Melosky, Cheryl Ho, 2022, Current oncology.

A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.

A. Karsan, I. Bosdet, D. Ionescu, 2014, Lung cancer.

Integrative genomic analysis of ghost cell odontogenic carcinoma.

Steven J. M. Jones, J. Schein, E. Pleasance, 2015, Oral oncology.

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

D. Gandara, P. Gumerlock, P. Mack, 2006, Clinical lung cancer.

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.

S. Yip, A. Karsan, I. Bosdet, 2021, Lung cancer.

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

D. Regier, Cheryl Ho, H. Lim, 2022, Current oncology.

Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes.

Cheryl Ho, J. Laskin, Jennifer Siegfried, 2017, Lung cancer.

Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.

J. Pantarotto, N. Leighl, P. Wheatley‐Price, 2016, Lung cancer.

Third-line chemotherapy in small-cell lung cancer: an international analysis.

Y. Summers, N. Leighl, P. Wheatley‐Price, 2014, Clinical lung cancer.

Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.

Jonn Wu, Cheryl Ho, J. Laskin, 2013, Journal of cancer research and therapeutics.

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation

L. Beckett, D. Gandara, A. Davies, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Population-based analysis of patients with advanced colorectal cancer: The impact of age on treatment and outcomes

S. Gill, Cheryl Ho, S. O'Reilly, 2005 .

EGFR mutation status on brain metastases from non-small cell lung cancer.

A. Nichol, Cheryl Ho, F. Hsu, 2016, Lung cancer.

High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.

M. Brauer, T. Dummer, J. Yee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-reported outcome measures in patients undergoing radiotherapy for head and neck cancer

Jonn Wu, V. Lapointe, E. Berthelet, 2020, Supportive Care in Cancer.

A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

P. Nathan, D. Wishart, M. Brudno, 2021, Canadian journal of kidney health and disease.

Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype

D. Ionescu, Cheryl Ho, Gang-ping Wang, 2020, Histopathology.

Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.

D. Gandara, P. Mack, A. Davies, 2007, Clinical lung cancer.

Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review

Sophie Sun, B. Melosky, Cheryl Ho, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rash severity and dose in phase I dose escalation cetuximab (C225) trial

L. Beckett, D. Gandara, P. Mack, 2008 .

Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years

Y. Wang, S. Lam, Jianjun Zhang, 2023, Current oncology.

Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36

J. Dancey, K. Ding, G. Nicholas, 2023, Cancer Research.

Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141

K. Harrington, M. Monga, E. Vokes, 2017 .

Untargeted Use of Targeted Therapy

D. Gandara, P. Gumerlock, P. Mack, 2008 .

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

C. McGahan, J. Hamm, Cheryl Ho, 2021, BMC cancer.

Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy.

M. Marra, K. Kasaian, Cheryl Ho, 2017, Current oncology.

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant

E. Pleasance, M. Marra, S. Yip, 2019, Cold Spring Harbor molecular case studies.

Clinical outcomes after whole genome sequencing in patients with metastatic non-small cell lung cancer.

Richard A. Moore, E. Pleasance, M. Marra, 2017 .

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non–Small-Cell Lung Cancer Clinical Trials

Cheryl Ho, N. Murray, J. Laskin, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.

Cheryl Ho, J. Laskin, K. M. Tong, 2015, Lung cancer.

EGFR-directed therapies to treat non-small-cell lung cancer

Cheryl Ho, J. Laskin, 2009, Expert opinion on investigational drugs.

Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.

Sophie Sun, B. Melosky, Cheryl Ho, 2014, Lung cancer.

Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review.

S. Lam, J. Yee, T. Shaipanich, 2014, Current oncology.

Dose Delivery Analysis of Weekly Versus 3-Weekly Cisplatin Concurrent With Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Jonn Wu, D. Hao, Cheryl Ho, 2014, American journal of clinical oncology.

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer

Y. Wang, Kelly Li, S. Yip, 2023, Current oncology.